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Abstract In human neutrophils, significant agonist-stimulated
superoxide anion (O32 ) release is observed only after exposure to
a priming agent such as TNFK. We have investigated the
potential for TNFK to modulate N-formyl-Met-Leu-Phe
(fMLP)-triggered Ins(1,4,5)P3 and PtdIns(3,4,5)P3 accumula-
tion. TNFK pretreatment did not affect basal or stimulated
Ins(1,4,5)P3 levels but greatly upregulated fMLP-stimulated
PtdIns(3,4,5)P3 accumulation, in a manner that matched, both
temporally and in magnitude, the increase in O32 generation
implying a possible role for PtdIns(3,4,5)P3 in signalling primed
O32 release.
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1. Introduction
Neutrophils are a vital component of the early non-speci¢c
immune response and hence patients who are neutropenic or
who have defective leukocyte function are highly susceptible
to bacterial infection [1]. However, neutrophils may also cause
tissue damage when activated prematurely or to excess, and
have been implicated in the pathogenesis of a wide variety of
in£ammatory diseases [2] including the adult respiratory dis-
tress syndrome [3].
The likelihood of neutrophil-mediated tissue damage is de-
termined largely by the activation status of these cells, which
can range from quiescent through primed to fully activated.
Whereas incubation of an unprimed neutrophil with a secre-
tagogue agonist induces only minimal cell activation, prior
exposure to a priming agent (which on its own is unable to
stimulate degranulation or O32 release) greatly ampli¢es the
magnitude of the response to an activating agonist [4]. The
wide variety of priming agents so far identi¢ed (e.g. lipopoly-
saccharide [4], tumour necrosis factor-K (TNFK) [5], granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) [6] and
platelet-activating factor [7]) has made it di⁄cult to dissect
out the signal transduction mechanism(s) underlying priming.
Activation of phospholipase A2 (PLA2) has been implicated in
neutrophil priming [8] and activation [9], but while the release
of arachidonic acid and O32 are both ‘primable’ events they
display di¡erent sensitivities to calcium in£ux and inhibition
of phosphoinositide 3-hydroxykinase (PI3K) [10], and when
released under physiological conditions arachidonic acid ap-
pears unable to stimulate or modulate O32 release [11].
Changes in intracellular calcium concentration ([Ca2]i) have
also been implicated in the priming process [12], but there
have been no studies detailing the e¡ects of priming agents
on secretagogue-induced Ins(1,4,5)P3 generation. To date,
only single time point measurements of the e¡ects of GM-
CSF priming on fMLP-stimulated Ins(1,4,5)P3 have been re-
ported, which show either enhanced [13] or unaltered [14]
Ins(1,4,5)P3 accumulation.
In addition to activating phosphoinositidase C (PIC), many
neutrophil secretagogues also stimulate PI3K, resulting in the
formation of PtdIns(3,4,5)P3 from PtdIns(4,5)P2 [15]. The
ability of wortmannin, a speci¢c and irreversible PI3K inhib-
itor, to abolish both fMLP- and phagocytosis-induced respi-
ratory burst activity in the absence of any e¡ect on agonist-
induced [Ca2]i £uxes, phorbol ester-mediated NADPH oxi-
dase activation or granule exocytosis [16^18] has provided
evidence in support of a central second-messenger role for
PtdIns(3,4,5)P3 in O32 generation.
In view of the apparently independent but obligatory roles
played by PtdIns(3,4,5)P3 and Ins(1,4,5)P3 in stimulating
NADPH oxidase activity in the neutrophil [16], and the un-
certainty regarding the mechanisms underlying the ability of
priming agents to facilitate agonist-stimulated O32 generation,
we have investigated the e¡ects of the archetypal priming
agent TNFK on fMLP-induced PIC and PI3K activation.
We demonstrate that priming of human neutrophils by
TNFK has no e¡ect on fMLP-induced Ins(1,4,5)P3 formation
but results in a major enhancement of fMLP-stimulated
PtdIns(3,4,5)P3 accumulation, the degree and timing of which
match precisely the priming of the O32 response. These data
suggest that PtdIns(3,4,5)P3 may be instrumental in signalling
the primed release of O32 , with TNFK acting to enhance the
e⁄cacy of fMLP receptor coupling to PI3K.
2. Materials and methods
2.1. Materials
Cytochrome c, fMLP, superoxide dismutase, and phosphate-bu¡-
ered saline (PBS) were purchased from Sigma Chemical Company
(Poole, Dorset, UK). Sterile phosphate-free HEPES-bu¡ered Hanks
solution was obtained from Gibco (Life Technologies Ltd., Renfrew-
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shire, UK). Human recombinant TNFK (Genzyme, Cambridge, MA)
was stored at 370‡C and diluted in PBS or phosphate-free bu¡er
immediately prior to use. Percoll was obtained from Pharmacia (Upp-
sala, Sweden) and Ins(1,4,5)P3 from Research Biochemicals Interna-
tional (St Albans, UK). [32P]Pi (40 mCi/ml in HCl- and carrier-free
aqueous solution), and [3H]Ins(1,4,5)P3 (17^20 Ci/mmol) were sup-
plied by DuPont (UK) Ltd. (Stevenage, UK). Partisphere SAX
HPLC columns were obtained from Whatman Chromatography
(Maidstone, UK) and polyethyleneimine (PEI) TLC plates from Cam-
Lab (Cambridge, UK). All other reagents were purchased from BDH
(Leicestershire, UK).
2.2. Preparation of human neutrophils
Human peripheral blood neutrophils were prepared using dextran
sedimentation and centrifugation through discontinuous plasma-Per-
coll gradients as previously described [19]. Sterile, LPS-free reagents
and plasticware were used throughout. Neutrophils were routinely
s 98% viable (trypan blue exclusion) and s 95% pure, with 6 0.1%
mononuclear cell contamination (cytospin and £ow cytometry).
2.3. TNFK priming of superoxide anion (O32 ) release
Neutrophils (106/100 Wl) were incubated with TNFK (10^10 000 U/
ml) in PBS containing divalent cations (2.3 mM CaCl2, 0.48 mM
MgCl2) in a shaking water bath at 37‡C for 30 min. Pre-warmed
cytochrome c (¢nal concentration 1.2 mg/ml in PBS) and fMLP
(100 nM) or vehicle (¢nal DMSO concentration 6 0.001%, v/v)
were added and O32 release calculated from the superoxide dismu-
tase-inhibitable reduction of cytochrome c. The kinetics of O32 release
were also measured by lucigenin-dependent chemiluminescence
(LDCL) using a ML 3000 microtitre plate luminometer (Dynatech
Laboratories Ltd, Billinghurst, UK). Lucigenin (0.25 mM in PBS
containing 1 mg/ml BSA) was added (100 Wl) to each well and allowed
to equilibrate at 37‡C for 15 min prior to the addition of 80 Wl
(1U106) of TNFK primed (100 U/ml) or unprimed cells. Bu¡er
(20 Wl) or fMLP (100 nM) was added to each of the wells and chemi-
luminescence recorded continuously at 14-s intervals for 12 min. Data
were recorded on-line (Cellular Chemiluminescence, Dynatech Labo-
ratories Ltd) to produce mean LDCL values from triplicate wells.
2.4. Measurement of fMLP-stimulated Ins(1,4,5)P3 accumulation
Neutrophils (225-Wl aliquots of 32.2U106 cells/ml) in PBS contain-
ing divalent cations were incubated with TNFK (100 U/ml) or PBS for
30 min at 37‡C prior to stimulation with fMLP (1 or 100 nM) or PBS.
Reactions (300 Wl) were stopped at 0^120 s by the addition of 60 Wl
ice-cold 3 M trichloroacetic acid (TCA). Neutralised extracts were
prepared by the addition of 75 Wl 10 mM EDTA (pH 7.0) and
300 Wl 1,1,2-trichlorotri£uoroethane/tri-n-octylamine (1:1, v/v) to
300 Wl of the TCA extracts. The pH of the upper phase was adjusted
to 7.0 using 60 mM NaHCO3 and Ins(1,4,5)P3 mass determined by
radioreceptor assay as previously detailed [20].
2.5. Measurement of fMLP-stimulated [32P]PtdIns(3,4,5)P3
accumulation
Neutrophils were washed twice in sterile, phosphate-free HEPES-
bu¡ered Hanks solution (110 mM NaCl, 10 mM KCl, 1 mM MgCl2,
10 mM glucose, 1.5 mM CaCl2, 30 mM HEPES, pH 7.4) and resus-
pended (108 cells in 2.25 ml bu¡er) with 5 mCi [32P]Pi. The cells were
incubated at 37‡C in a shaking water bath for 70 min, washed twice
and resuspended in 1.2 ml phosphate-free bu¡er. Aliquots (100 Wl)
were incubated for 30 min with TNFK (100 U/ml) or bu¡er, and
stimulated with fMLP (100 nM) or vehicle for 10 or 60 s. Reactions
were stopped with 675 Wl methanol/chloroform (2:1, v/v). Samples
were acidi¢ed by the addition of 158 Wl of 2.4 M HCl/5 mM tetrabu-
tyl-ammonium sulphate and partitioned using 675 Wl chloroform. The
lower phase was washed with 658 Wl synthetic upper phase (metha-
nol:HCl:chloroform, 48:47:3, v/v/v), dried under vacuum and the
lipids deacylated with monomethylamine reagent. Deacylated lipids
were extracted in the presence of 200 Wl phytate hydrolysate (12 mg
phosphorus per sample) with 240 Wl n-butanol/light petroleum/ethyl-
formate (20:4:1, v/v/v) and the lower phase dried. The [32P]glycero-
phosphoesters were dissolved in 2 ml H2O and resolved by anion-
exchange HPLC on a Partisphere SAX column. In experiments where
resolution of [32P]glycerophosphoester isomers was not required, sam-
ples were redissolved in 2 ml 20 mM HCl, 1 mM K2PO4 chromato-
graphed on polyethyleneimine-cellulose plates and developed in
0.48 M HCl. The radioactivity in the [32P]GroPInsP3 spots was quan-
ti¢ed using a phosphoimager (Molecular Dynamics).
3. Results
3.1. TNFK priming of O32 generation in human neutrophils
Unprimed neutrophils released minimal quantities of O32
when challenged with a maximal concentration of fMLP
(Fig. 1A,B). Priming with TNFK for 30 min resulted in a
concentration-dependent increase in fMLP-stimulated O32
generation (Fig. 1A). Since TNFK at 100 U/ml ampli¢ed
fMLP-induced O32 release by 4.5-fold and had no e¡ect on
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Fig. 1. TNFK priming of fMLP-stimulated O32 generation in human
neutrophils: concentration response and time course. Human neu-
trophils were incubated with 0^10 000 U/ml TNFK for 30 min prior
to stimulation with bu¡er (open bars) or 100 nM fMLP (closed
bars). Quanti¢cation of O32 release (A) during a 10 min incubation
with fMLP by superoxide dismutase-inhibitable reduction of cyto-
chrome c (data points represent mean þ S.E.M. of three separate ex-
periments each performed in triplicate) and (B) with lucigenin-
dependent chemiluminescence (LDCL), monitored at 14-s cycle in-
tervals in: control unprimed cells (a), TNFK-primed (100 U/ml,
30 min) unstimulated cells (E), unprimed fMLP (100 nM)-stimulated
cells (b) and TNFK-primed, fMLP-stimulated cells (F). Data are
from a single experiment, representative of four.
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spontaneous O32 production, this concentration was used in
subsequent experiments. Analysis of the kinetics of O32 release
following fMLP stimulation (Fig. 1B) revealed that this re-
sponse was rapid (onset within 14 s, peak at 60^90 s) and both
augmented and prolonged following TNFK priming.
3.2. Ins(1,4,5)P3 generation in TNFK primed and unprimed
neutrophils
Stimulation of unprimed neutrophils with 100 nM fMLP
(a maximal stimulus for Ins(1,4,5)P3 and O32 generation,
data not shown) caused a rapid and transient elevation of
Ins(1,4,5)P3 reaching a value 4-fold higher than resting levels
at 10 s and thereafter declining to control levels by 60 s
(Fig. 2A). Incubation with TNFK (100 U/ml) for 30 min (con-
ditions that induced a major upregulation in the O32 response)
altered neither basal nor fMLP-stimulated Ins(1,4,5)P3 levels
(Fig. 2A). TNFK also failed to in£uence the time course of
Ins(1,4,5)P3 accumulation following stimulation with a sub-
maximal (EC40) concentration of fMLP (1 nM) (Fig. 2B).
Ins(1,4,5)P3 mass was also determined at 5 and 10 min follow-
ing fMLP stimulation and again, no signi¢cant di¡erences
were observed between primed and unprimed cells (data not
shown).
3.3. [32P]PtdIns(3,4,5)P3 generation in TNFK-primed and
unprimed neutrophils
Use of sterile, endotoxin- and phosphate-free HEPES-buf-
fered Hanks solution and a 70 min incubation with 2 mCi/
ml of [32P]Pi permitted su⁄cient [32P]PtdIns(4,5)P2 labelling
to quantify changes in [32P]PtdIns(3,4,5)P3 levels yet did not
abrogate the O32 priming response or induce sponta-
neous O32 generation (Fig. 3). Basal and fMLP-stimulated
[32P]PtdIns(3,4,5)P3 accumulation was quanti¢ed at both 10 s
(to correspond with the time of peak Ins(1,4,5)P3 and
[32P]PtdIns(3,4,5)P3 accumulation in unprimed cells ; Fig. 2
and [15]) and 60 s (to correspond with the peak primed O32
response; Fig. 1B) following fMLP addition, with O32 assayed
in parallel. While TNFK alone (100 U/ml, 30 min) did not
a¡ect basal [32P]PtdIns(3,4,5)P3 levels, it enhanced the fMLP-
stimulated [32P]PtdIns(3,4,5)P3 signal by 1.4-fold at 10 s (Ta-
ble 1), and more dramatically by 6.2-fold at 60 s (Table 1 and
Fig. 3). As shown in Table 1 there was a substantial (s 100-
fold) increase in [32P]PtdIns(3,4,5)P3 accumulation in the
TNFK primed, fMLP-stimulated cells compared to levels in
control unstimulated cells. This ability of TNFK to augment
fMLP-stimulated [32P]PtdIns(3,4,5)P3 matched precisely the
observed increases in O32 generation when measured under
identical conditions (Fig. 3).
3.4. E¡ects of TNFK and fMLP on [32P]phosphoinositide
metabolism
Incubation of [32P]Pi-labelled neutrophils with 100 U/ml
TNFK for 30 min resulted in a small but signi¢cant increase
in [32P]PtdIns4P levels but no consistent e¡ect on
[32P]PtdIns(4,5)P2, the immediate precursor of PtdIns(3,4,5)P3
(Table 1). The changes in [32P]PtdIns(3,4,5)P3 were paralleled
very closely by changes in its immediate metabolite
[32P]PtdIns(3,4)P2, indicating that the ability of TNFK to aug-
ment fMLP-stimulated [32P]PtdIns(3,4,5)P3 accumulation
does not re£ect inhibition of its metabolism. Following 10 s
fMLP stimulation, very similar changes in [32P]PtdIns(3,4)P2
and [32P]PtdIns3P levels were observed in both primed and
unprimed cells whilst at 60 s post fMLP stimulation the ac-
cumulation of both phosphoinositides was much greater in
primed cells (Table 1) and mirrored the changes observed in
[32P]PtdIns(3,4,5)P3 levels. At 60 s following fMLP stimula-
tion, depletion of [32P]PtdIns(4,5)P2 was also much greater in
the primed cells.
4. Discussion
We have demonstrated that priming of human neutrophils
by TNFK results in a considerable enhancement of fMLP-
induced [32P]PtdIns(3,4,5)P3 accumulation. The time course
and magnitude of this response match precisely the e¡ect of
TNFK on fMLP-stimulated O32 generation suggesting that
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Fig. 2. E¡ect of TNFK priming on fMLP-stimulated Ins(1,4,5)P3
mass in human neutrophils. Human neutrophils were incubated with
TNFK 100 U/ml (circles) or PBS (squares) at 37‡C for 30 min and
stimulated with fMLP (closed symbols) or PBS (open symbols). The
concentration of fMLP used was 100 nM in A and 1 nM (EC40) in
B. Ins(1,4,5)P3 mass was determined in neutralised TCA extracts by
radioreceptor assay. Data represent mean þ S.E.M. for three sepa-
rate experiments each performed in duplicate.
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PtdIns(3,4,5)P3 may play a vital role in signalling the primed
release of O32 . In contrast, TNFK did not in£uence fMLP-
stimulated Ins(1,4,5)P3 accumulation.
The mechanism whereby TNFK enhances fMLP-induced
PtdIns(3,4,5)P3 accumulation in neutrophils, and the down-
stream e¡ectors of PtdIns(3,4,5)P3 that result in O32 genera-
tion, are at present, unknown. Under the conditions employed
in this study we have previously shown that the priming e¡ect
of TNFK is mediated exclusively by stimulation of the p55
TNFK receptor (TNF-R1) [21] and is not mimicked by cera-
mide [22]. Current knowledge of TNF-R1 signalling protein
interactions provides little insight into how this receptor may
interact with phospholipid signalling pathways. Since there
was no apparent increase in PtdIns(4,5)P2 substrate availabil-
ity or obvious inhibition of PtdIns(3,4,5)P3-5 phosphatase ac-
tivity (as judged from the similar increases in
[32P]PtdIns(3,4)P2 levels), it is likely that TNFK acts directly
at the level of the PI3K, or at a more proximal transduction
step, and does not relate to the reported ability of TNFK to
enhance agonist-stimulated phospholipase D activity [23].
Furthermore, the fact that fMLP-stimulated Ins(1,4,5)P3 ac-
cumulation was not increased by TNFK strongly suggests that
the enhanced [32P]PtdIns(3,4,5)P3 response does not re£ect a
change in plasma membrane fMLP receptor or Gi2K expres-
sion or enhanced GLQ release [24]. The possibility that TNFK
induces the recruitment of a tyrosine kinase-regulated PI3K to
augment, or work in parallel with, the GLQ -regulated PI3K is
supported by the recent demonstration [25] that fMLP and
insulin exert a synergistic e¡ect on PtdIns(3,4,5)P3 formation
in THP1 cells, suggesting that there may be cross-talk between
the tyrosine phosphorylation-dependent and the G-protein-
dependent PI3K pathways.
Whilst PtdIns(3,4,5)P3 generation has been implicated in a
variety of cellular processes [26], the precise role(s) of
PtdIns(3,4,5)P3 and its immediate product PtdIns(3,4)P2 re-
mains to be elucidated. Studies in a variety of cell lines, uti-
lising receptor and enzyme mutants and PI3K inhibitors, have
suggested that PI3K may lie upstream of several protein ki-
nase cascades, including p70 S6 kinase [27], the MAPK path-
way [28] and the serine-threonine kinase Akt-1/PKB [29];
however, the relevance of these observations to O32 generation
in neutrophils is at present unclear. Activation of Ca2-inde-
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Fig. 3. E¡ect of TNFK priming on fMLP-stimulated [32P]PtdIns(3,4,5)P3 accumulation and superoxide generation in human neutrophils. Left
panel: Human neutrophils were suspended in phosphate-free bu¡er and labelled in bulk with 5 mCi [32P]Pi for 70 min at 37‡C. Cells were sub-
sequently washed and incubated for 30 min with TNFK (100 U/ml) or bu¡er. Following 60 s stimulation with fMLP (100 nM) the reactions
were quenched and [32P]PtdIns(3,4,5)P3 levels determined by TLC as detailed. Data represent mean of % maximum responses for three separate
experiments each performed in triplicate. S.E.M.s were all 6 5% of individual values. Right panel: Human neutrophils derived from the same
cell preparations as used above and incubated and primed in an identical manner were stimulated with bu¡er or fMLP (100 nM) for 10 min in
the presence of cytochrome c to allow measurement of O32 release. Data (expressed as % of maximum response) represent mean þ S.E.M. from
three separate experiments. Where not shown, S.E.M.s were 6 5% of individual values.
Table 1
E¡ects of TNFK on fMLP-stimulated changes in human neutrophil [32P]phosphoinositide levels
PtdIns4P PtdIns(4,5)P2 PtdIns3P PtdIns(3,4)P2 PtdIns(3,4,5)P3
Control 10 s 39 þ 3 100 1.3 þ 0.1 0.07 þ 0.01 0.23 þ 0.39
60 s 40 þ 3 100 1.0 þ 0.2 0.10 þ 0.02 0.13 þ 0.01
TNF 10 s 58 þ 1 119 þ 6 1.9 þ 0.1 0.12 þ 0.01 0.29 þ 0.09
60 s 55 þ 3 95 þ 9 1.6 þ 0.1 0.16 þ 0.02 0.12 þ 0.01
fMLP 10 s 37 þ 2 80 þ 4 1.4 þ 0.1 0.97 þ 0.07 4.10 þ 0.24
60 s 45 þ 1 91 þ 1 1.3 þ 0.1 1.28 þ 0.12 2.22 þ 0.15
TNF+fMLP 10 s 54 þ 2 100 þ 5 20 þ 0.2 1.35 þ 0.10 6.49 þ 0.26
60 s 49 þ 2 65 þ 1 2.6 þ 0.2 9.76 þ 0.85 13.78 þ 1.47
[32P]Pi-labelled human neutrophils were incubated in the presence or absence of 100 U/ml TNFK for 30 min prior to stimulation with bu¡er or
100 nM fMLP. Reactions were quenched at 10 s or 60 s and the lipids extracted and deacylated as described. The [32P]glycerophosphoesters were
resolved by HPLC using a Partisphere SAX column. To permit a clearer understanding of the relative amounts of 32P-labelled 3-phosphoinositides
in neutrophils, and the changes observed under the de¢ned conditions, data are expressed as per cent of control [32P]PtdIns(4,5)P2 dpm values
(41 027 þ 2232 dpm, experiment quenched at 10 s; 24 062 þ 830 dpm, experiment quenched at 60 s). The results shown are mean þ S.E.M. of
triplicate determinations from a single representative experiment.
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pendent isoforms of PKC by PtdIns(3,4,5)P3 has also been
demonstrated [30] ; since p47phox phosphorylation represents
a key step in NADPH oxidase assembly and can be induced
by PKC activation, this represents a potential mechanism by
which PI3K could in£uence O32 generation. However, activa-
tion of PKC by alternative routes (e.g. PIC-mediated increases
in [Ca2]i and diacylglycerol levels) also occurs during fMLP
stimulation, hence PKC is unlikely to be the sole
PtdIns(3,4,5)P3 e¡ector pathway involved. The small G-pro-
tein p21rac, whose translocation to the neutrophil membrane is
essential for O32 generation [31], is also a downstream target
of PtdIns(3,4,5)P3 [32], and increased translocation of p21rac
may lead to an enhanced O32 response [33].
Forehand and colleagues have previously demonstrated a
small enhancement of fMLP-stimulated [Ca2]i responses in
lipopolysaccharide-primed neutrophils [12]. Our results indi-
cate that such di¡erences are unlikely to result from priming-
induced changes in Ins(1,4,5)P3 formation or metabolism.
Calcium studies performed at a single cell level, however, in-
dicate that priming probably results from the recruitment of
only a proportion of cells into a more highly agonist-respon-
sive pool [34]. Hence in view of the marked heterogeneity that
may exist in the density of Ins(1,4,5)P3-sensitive Ca2 chan-
nels within intracellular Ca2 stores [35], small or localised
changes in Ins(1,4,5)P3 could conceivably still contribute to
signalling the primed state, with the current mass assay not
su⁄ciently sensitive to detect such changes.
In summary, we have demonstrated that fMLP-stimulated
PtdIns(3,4,5)P3, but not Ins(1,4,5)P3, accumulation is aug-
mented in TNFK-primed human neutrophils and that this
e¡ect mirrors very closely the ability of TNFK to enhance
fMLP-mediated O32 generation. These data, together with
the documented ability of wortmannin to abolish respiratory
burst activity in these cells, suggest that enhanced
PtdIns(3,4,5)P3 accumulation may represent a key mechanism
underlying the ability of priming agents to modulate secreta-
gogue-stimulated O32 generation.
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